Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | CISD1 | Q9NZ45 | 6/20 | 0.51 |
| ▸ | PLK1 | P53350 | 6/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.50 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.50 |
| ▸ | KDM6B | O15054 | 1/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.49 |
| ▸ | METAP2 | P50579 | 1/20 | 0.48 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.48 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1628988 | 0.86 | KDM4E (0.48) | KDM4EPKMCISD1PLK1HCAR3 | |
| SCHEMBL3396257 | 0.86 | KDM4E (0.52) | KDM4EPKMPLK1HCAR3PLK3 | |
| SCHEMBL28109945 | 0.84 | PLK1 (0.67) | CISD1PLK1HCAR3PLK3 | |
| SCHEMBL1884483 | 0.82 | CISD1 (0.63) | KDM4ECISD1PLK1HCAR3KDM6B | |
| SCHEMBL7356043 | 0.82 | PLK1 (0.53) | CISD1PLK1HCAR3KDM6BKDM4C | |
| SCHEMBL8383497 | 0.81 | CISD1 (0.55) | CISD1PLK1HCAR3KDM6BKDM4C | |
| SCHEMBL1082290 | 0.81 | KDM6B (0.51) | CISD1PLK1HCAR3KDM6BKDM4C | |
| SCHEMBL466141 | 0.78 | PLK1 (0.63) | KDM4EPLK1KDM6BKDM4CPLK3 | |
| SCHEMBL3843127 | 0.78 | KMT2A (0.71) | PKMHCAR3 | |
| SCHEMBL15636197 | 0.78 | KDM6B (0.54) | KDM4EPKMCISD1PLK1HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144872-A1 | New Methylenebisphenyl Compounds Useful in the Treatment of Inflammation | BIOLIPOX AB | 2010-06-10 | — | — | US | disclosed |
| EP-2132169-A1 | NEW METHYLENEBISPHENYL COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008107661-A1 | NEW METHYLENEBISPHENYL COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144872-A1 | New Methylenebisphenyl Compounds Useful in the Treatment of Inflammation | LTC4S, LTB4R2, LTB4R | KDM4E 2928/4885PKM 2566/4885CISD1 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.